Devonian Health Group Inc (GSD) - Total Liabilities

Latest as of January 2026: CA$1.67 Million CAD ≈ $1.21 Million USD

Based on the latest financial reports, Devonian Health Group Inc (GSD) has total liabilities worth CA$1.67 Million CAD (≈ $1.21 Million USD) as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Devonian Health Group Inc net asset momentum to track the company's year-over-year net asset growth rate.

Devonian Health Group Inc - Total Liabilities Trend (2015–2025)

This chart illustrates how Devonian Health Group Inc's total liabilities have evolved over time, based on quarterly financial data. See Devonian Health Group Inc (GSD) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Devonian Health Group Inc Competitors by Total Liabilities

The table below lists competitors of Devonian Health Group Inc ranked by their total liabilities.

Company Country Total Liabilities
Dare Bioscience Inc
NASDAQ:DARE
USA $29.63 Million
Canuc Resources Corp
V:CDA
Canada CA$239.20K
Stern Groep N.V.
AS:PBH
Netherlands €595.00K
SOLWERS OYJ EO 1
F:0ST
Germany €56.34 Million
Predictive Oncology Inc
NASDAQ:POAI
USA $80.57 Million
Sensei Biotherapeutics Inc
NASDAQ:SNSE
USA $14.19 Million
Rocketdna Ltd
AU:RKT
Australia AU$3.53 Million
Ortivus AB ser. B
ST:ORTI-B
Sweden Skr48.52 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Devonian Health Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Devonian Health Group Inc (GSD) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.56 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Devonian Health Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Devonian Health Group Inc (2015–2025)

The table below shows the annual total liabilities of Devonian Health Group Inc from 2015 to 2025.

Year Total Liabilities Change
2025-07-31 CA$6.69 Million
≈ $4.84 Million
-60.34%
2024-07-31 CA$16.87 Million
≈ $12.21 Million
+242.26%
2023-07-31 CA$4.93 Million
≈ $3.57 Million
-7.22%
2022-07-31 CA$5.31 Million
≈ $3.84 Million
-25.00%
2021-07-31 CA$7.08 Million
≈ $5.12 Million
-3.11%
2020-07-31 CA$7.31 Million
≈ $5.29 Million
+3.41%
2019-07-31 CA$7.07 Million
≈ $5.12 Million
+10.10%
2018-07-31 CA$6.42 Million
≈ $4.65 Million
+90.57%
2017-07-31 CA$3.37 Million
≈ $2.44 Million
-43.33%
2016-07-31 CA$5.95 Million
≈ $4.30 Million
+16718.26%
2016-06-30 CA$35.36K
≈ $25.58K
-99.46%
2015-07-31 CA$6.55 Million
≈ $4.73 Million
--

About Devonian Health Group Inc

V:GSD Canada Biotechnology
Market Cap
$18.61 Million
CA$25.72 Million CAD
Market Cap Rank
#25304 Global
#985 in Canada
Share Price
CA$9.25
Change (1 day)
+8.82%
52-Week Range
CA$0.13 - CA$14.00
All Time High
CA$14.00
About

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more